Oxeltis Revenue and Competitors

Montpellier Cedex 4,

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Oxeltis's estimated annual revenue is currently $5M per year.(i)
  • Oxeltis's estimated revenue per employee is $201,000

Employee Data

  • Oxeltis has 25 Employees.(i)
  • Oxeltis grew their employee count by -11% last year.

Oxeltis's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$46.2M2305%N/AN/A
#2
$43.8M21821%N/AN/A
#3
$57.1M28426%N/AN/A
#4
$24.5M1223%N/AN/A
#5
$52.9M26313%N/AN/A
#6
$24.7M12313%N/AN/A
#7
$1.8M180%$114.3MN/A
#8
$7.2M36-20%N/AN/A
#9
$13.7M68-7%N/AN/A
#10
$7.6M39-13%$123.9MN/A
Add Company

What Is Oxeltis?

OXELTIS is an independent medchem oriented service company managed by former researchers from Idenix Pharmaceuticals and located in Montpellier - France. Oxeltis is a company that delivers integrated solutions for managing and executing medicinal and fine organic chemistry projects. We run FTE programs (hit to lead optimization) with an expertise in some specialty chemistry such as macrocycles (pseudopeptides), mono & poly/oligosaccharides (sugar phosphates, iminosugars, saccharidic antigens…) and nucleos(t)ides (modified nucleosides, phosphoramidites…) applied to discovery programs in oncology, antivirals and antibiotics mainly. OXELTIS client portfolio includes 35+ European and US companies from biotech to top 10 pharmaceutical companies. With its team of experienced medchem chemists, OXELTIS is proactive in providing rapid, high quality and competitive work. Specific expertise: - Contract research in medicinal chemistry, FTE programs for hit to lead optimization in different fields including antivirals, anticancer and antibiotics. - Fee-for-service custom synthesis expertise in heterocycles (in various fields), modified sugars (sugar phosphates, iminosugars, unnatural sugars…monosaccharides and oligosaccharides...), nucleoside/nucleotide (sugar and base-modified nucleosides, phosphoramidites…), macrocycles (e.g. antiviral antiproteases) .

keywords:N/A

N/A

Total Funding

25

Number of Employees

$5M

Revenue (est)

-11%

Employee Growth %

N/A

Valuation

N/A

Accelerator